Based on in vitro experiments, IGF-1 might serve as a potential therapeutic target for cirrhosis and intestinal barrier dysfunction via its inactivation of the TLR4/MyD88/NF-κB pathway [31]. This evidence concerns the gene IGF1 and Cirrhosis.